Table 2. Five-year age-standardised prevalence (AP, per 100 000)a, age-standardised incidence rate (AI, per 100 000)a, and 5-year relative survival (RS)b in the United States (SEER), Nordic Countries (NORDCAN), Italy (AIRTUM), Australia, and France with differences (Δ%) in comparison with the corresponding estimates in the United States. MEN, all ages.

		Nordic Countries		Italy		Australia		France
Site (ICD10)	United States		Δ%		Δ%		Δ%		Δ%
All cancers excluding non-melanoma
AP	1655	1175	−29	1405	−15	1470	−11	1271	−23
AI	542	415	−23	500	−8	509	−6	494	−9
RS	67%	55%	−18	52%	−22	58%	−12	46%	−31
Oesophagusc (C15)
AP	12	7	−43	7	−42	—	—	18	51
AI	8	6	−23	6	−23	—	—	14	86
RS	17%	9%	−47	10%	−43	—	—	12%	−34
Stomach (C16)
AP	19	17	−9	45	143	21	16	23	22
AI	10	12	19	26	152	13	29	14	40
RS	24%	20%	−18	30%	24	24%	1	23%	−3
Colon and rectum (C18–C21)
AP	186	152	−18	206	11	224	21	172	−7
AI	58	51	−13	64	10	71	22	60	2
RS	66%	56%	−16	59%	−11	61%	−8	57%	−14
Liver (C22)
AP	11	4	−65	31	170	8	−30	15	30
AI	9	5	−40	21	144	6	−29	16	81
RS	11%	6%	−43	15%	39	3%	−69	8%	−27
Pancreas (C25)
AP	10	8	−21	11	11	7	−27	7	−28
AI	12	11	−12	13	8	10	−16	9	−27
RS	5%	4%	−22	6%	12	5%	−16	8%	44
Trachea, bronchus, and lung (C33–C34)
AP	95	51	−46	95	0	63	−34	99	4
AI	76	49	−36	81	6	58	−24	70	−7
RS	14%	10%	−30	13%	−6	11%	−23	12%	−13
Skin melanoma (C43)
AP	99	70	−30	53	−47	226	127	37	−62
AI	23	16	−29	12	−47	53	132	11	−53
RS	91%	83%	−9	80%	−12	90%	−1	82%	−10
Prostate (C61)
AP	732	521	−29	397	−46	509	−30	431	−41
AI	176	120	−32	88	−50	119	−32	122	−30
RS	98%	78%	−21	87%	−12	85%	−13	78%	−20
Kidney (C64–66, C68)
AP	62	33	−46	68	10	45	−28	50	−20
AI	18	12	−36	19	5	14	−24	16	−10
RS	63%	52%	−18	67%	7	66%	4	60%	−5
Bladder (C67, D09.0, D30.3, 41.4)
AP	132	105	−20	185	40	52	−61	66	−50
AI	34	31	−7	50	48	18	−46	23	−32
RS	83%	74%	−11	78%	−6	62%	−25	63%	−24
Brain (C70–C72)
AP	15	37	143	16	5	14	−9	14	−8
AI	8	13	59	9	14	8	3	7	−12
RS	25%	21%	−16	21%	−17	13%	−47	17%	−31
Thyroid (C73)
AP	21	8	−61	26	25	14	−35	16	−21
AI	4	2	−55	5	14	3	−33	4	−12
RS	92%	79%	−15	88%	−5	88%	−5	75%	−18
Hodgkin lymphoma (C81)
AP	13	11	−15	17	33	10	−20	11	−18
AI	3	3	−19	4	29	2	−22	3	−14
RS	80%	85%	6	81%	2	85%	6	77%	−4
Non-Hodgkin lymphoma (C82–C85, C96)
AP	78	48	−38	62	−21	66	−16	38	−51
AI	23	15	−35	18	−21	20	−12	15	−33
RS	62%	55%	−12	59%	−5	62%	−1	49%	−21
Multiple myelomac (C90)d
AP	18	14	−20	19	5	19	3	16	−9
AI	7	6	−19	7	3	7	0	5	−26
RS	37%	36%	−5	46%	23	—	—	39%	3
Leukaemias (C91–C95)
AP	47	35	−25	34	−27	42	−9	34	−27
AI	16	12	−25	14	−13	13	−21	13	−16
RS	48%	56%	15	45%	−7	48%	−1	51%	5

^aStandardised on the European population.

^bStandardised on the International Cancer Survival Standards.

^cUnavailable data are represented by ‘—'.

^dC88 is also included in Italy (4.4% of C88 and C90 cases in men).